These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23588081)

  • 21. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soft-tissue sarcomas in adults.
    Clark MA; Fisher C; Judson I; Thomas JM
    N Engl J Med; 2005 Aug; 353(7):701-11. PubMed ID: 16107623
    [No Abstract]   [Full Text] [Related]  

  • 24. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
    Benjamin RS; Debiec-Rychter M; Le Cesne A; Sleijfer S; Demetri GD; Joensuu H; Schöffski P; Poveda A
    Semin Oncol; 2009 Aug; 36(4):302-11. PubMed ID: 19664491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
    Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
    Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
    [No Abstract]   [Full Text] [Related]  

  • 28. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer: Oncogenes in context.
    Heinrich MC; Corless CL
    Nature; 2010 Oct; 467(7317):796-7. PubMed ID: 20944735
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
    Han H; Yu YY; Wang YH
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S80-3. PubMed ID: 19119132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical update on adult and pediatric gastrointestinal stromal tumor. Preface.
    Trent JC; Patel SR
    Hematol Oncol Clin North Am; 2009 Feb; 23(1):xiii-xiv. PubMed ID: 19248966
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [GIST refractory to imatinib treatment].
    Onozawa Y; Terashima M
    Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
    Wang CM; Shi YQ; Fu H; Zhao GF; Zhou Y; Du CY; Ye YW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May; 13(5):371-4. PubMed ID: 20499309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview.
    Sartini S; Dario B; Morelli M; Da Settimo F; La Motta C
    Curr Med Chem; 2011; 18(19):2893-903. PubMed ID: 21651490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
    Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
    J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-KIT in uveal melanoma: big fish or red herring?
    Daniels AB; Abramson DH
    Arch Ophthalmol; 2009 May; 127(5):695-7. PubMed ID: 19433723
    [No Abstract]   [Full Text] [Related]  

  • 40. Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.
    Hagemann IS; Govindan R; Javidan-Nejad C; Pfeifer JD; Cottrell CE
    J Thorac Oncol; 2014 Feb; 9(2):e12-6. PubMed ID: 24419427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.